Bristol Continues To Refocus Marketing By Outsourcing Cefzil And Tequin
This article was originally published in The Pink Sheet Daily
Executive Summary
Ventiv will commit 375 reps to focus on the primary care market while Bristol will continue to sell the antibiotics to specialists in hospitals. The two companies had terminated a previous co-promotion agreement for Cefzil; the new contract is fee-for-service and does not include risk sharing.
You may also be interested in...
Rumors Of Big Pharma Sales Force Cuts Could Boost Smaller Contracts For Ventiv
Small and mid-sized companies are more likely to seek contractors rather than enter into partnering deals with big pharma companies, Ventiv CEO Broshy says. Strong demand for CSO services is likely to continue among smaller companies as they make up a larger proportion of approved NDA holders.
Rumors Of Big Pharma Sales Force Cuts Could Boost Smaller Contracts For Ventiv
Small and mid-sized companies are more likely to seek contractors rather than enter into partnering deals with big pharma companies, Ventiv CEO Broshy says. Strong demand for CSO services is likely to continue among smaller companies as they make up a larger proportion of approved NDA holders.
Primary Care Sales Force Downsizing Will Continue, Bristol Says
Bristol-Myers Squibb expects additional downsizing of its primary care sales force as it shifts its product portfolio to specialty care, Exec VP Donald Hayden told analysts July 29